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The virologic test results of 415 patients with severe
acute respiratory syndrome (SARS) were examined. The
peak detection rate for SARS-associated coronavirus
occurred at week 2 after illness onset for respiratory speci-
mens, at weeks 2 to 3 for stool or rectal swab specimens,
and at week 4 for urine specimens. The latest stool sample
that was positive by reverse transcription–polymerase chain
reaction (RT-PCR) was collected on day 75 while the patient
was receiving intensive care. Tracheal aspirate and stool
samples had a higher diagnostic yield (RT-PCR average
positive rate for first 2 weeks: 66.7% and 56.5%, respective-
ly). Pooled throat and nasal swabs, rectal swab, nasal swab,
throat swab, and nasopharyngeal aspirate specimens pro-
vided a moderate yield (29.7%–40.0%), whereas throat
washing and urine specimens showed a lower yield (17.3%
and 4.5%). The collection procedures for stool and pooled
nasal and throat swab specimens were the least likely to
transmit infection, and the combination gave the highest
yield for coronavirus detection by RT-PCR. Positive virolog-
ic test results in patient groups were associated with
mechanical ventilation or death (p < 0.001), suggesting a
correlation between viral load and disease severity.
Severe acute respiratory syndrome (SARS) is a newhuman disease caused by a novel coronavirus, SARS-
associated coronavirus (SARS-CoV) (1–5). In Hong
Kong, the first recognized outbreak of SARS occurred in
early March 2003 in the Prince of Wales Hospital (6,7).
Subsequently, outbreaks were reported from other hospi-
tals and from the community (8). As of September 26,
2003, 8,098 cases had been reported to the World Health
Organization (WHO) from 29 cities, 1,755 of which were
found in Hong Kong (9). No new cases have been found in
Hong Kong since June 11, 2003, and on June 23, 2003,
WHO removed Hong Kong from the list of areas with
local transmission (10). Since identification of the culprit
virus in late March 2003, a network has been set up in
Hong Kong to provide centralized laboratory diagnostic
services for patients with suspected cases of SARS. The
diagnostic approach was based on a combination of sero-
logic testing, reverse transcription–polymerase chain reac-
tion (RT-PCR), and virus isolation. Here, we report our
experience with the laboratory diagnosis for SARS-CoV
infection during this outbreak in Hong Kong, with
emphases on the viral shedding pattern, the diagnostic
yield of various specimen types, and detection methods.
Materials and Methods
Patients
This retrospective study analyzed laboratory records of
patients admitted to six public hospitals in Hong Kong dur-
ing the SARS epidemic from March to June 2003. The first
inclusion criterion was serologic evidence of SARS-CoV
infection. Altogether, 433 patients who exhibited either
seroconversion or a fourfold rise in anti–SARS-CoV
immunoglobulin (Ig) G antibody titer were identified.
Detection of anti-SARS-CoV IgG antibody was based on
an in-house immunofluorescence assay that used virus-
infected cells. Of the 433 patients with positive serologic
test results, 18 were excluded because no samples had
been collected for virus detection. As a result, 415 patients
were included in this study. Twelve were pediatric patients
3–16 years of age (mean 11.3, standard deviation [SD]
4.1), divided equally between girls and boys. Three hun-
dred thirty-five were adult patients 17–64 years of age
(mean 37.1, SD 11.2), with 60.9% females. The remaining
68 were elderly patients 65–97 years of age (mean 76.7,
SD 8.2), with 37 (54.4%) women. Altogether, 48/335
(14.3%) of the adult group and 2/68 (2.9%), respectively,
of the elderly group required ventilation and received
intensive care but recovered; 4/335 (1.2%) of adults and
21/68 (30.9%) of elderly patients died of the infection. All
children recovered without requiring mechanical ventila-
tion or intensive care.
Specimen Collection
Respiratory, stool, and rectal swab specimens were col-
lected in viral transport medium, and urine samples were
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transported in sterile containers. For some patients, throat
and nasal swab samples were pooled into a single speci-
men container and processed as a single specimen. These
samples were referred as “pooled throat and nasal swabs”
for the purpose of analysis in this study. Specimens col-
lected were refrigerated (approximately 10°C) until deliv-
ery, which were done on the same day in most
circumstances. Specimens were kept in iceboxes during
delivery to the designated centralized laboratory. SARS-
CoV investigations were performed on fresh specimens
without prior freezing and thawing. 
Viral RNA Detection
SARS-CoV detection by RT-PCR was conducted in
two laboratories based on the same primer set COR-1
(sense) 5′ CAC CGT TTC TAC AGG TTA GCT AAC GA
3′, and COR-2 (antisense) 5′ AAA TGT TTA CGC AGG
TAA GCG TAA AA 3′ (11). The specimens were cen-
trifuged at 10,000 x g for 1 min, and 140 µL of the super-
natant were used for RNA extraction using the QIAamp
viral RNA Mini Kit (QIAGEN, Hilden, Germany) accord-
ing to the manufacturer’s protocol. Reverse transcription
of RNA was conducted in a 20-µL reaction mix containing
4.2 µL of extracted RNA preparation, 2.5 µmol/L of ran-
dom hexamer and 50 U of reverse transcriptase (Applied
Biosystems, Foster City, CA). After incubation at room
temperature for 10 min and at 42°C for 30 min, the reac-
tion was stopped by heating at 95°C for 5 min and chilled
on ice. The subsequent PCR was conducted in a 50-µL
reaction mix containing 5 µL of cDNA template, 1 µmol/L
of each primer COR-1 and COR-2, 1.5 U Taq polymerase
(Amersham Biosciences, Uppsala, Sweden), 0.2 mmol/L
of each deoxynucleoside triphosphate and 2.0 mmol/L
magnesium chloride. The cycling conditions were 94°C
for 3 min; 45 cycles of 94°C for 30 sec, 60°C for 30 sec,
and 72°C for 1 min, and a final extension at 72°C for 7
min. The PCR amplicons were visualized by ethidium bro-
mide staining after agarose gel electrophoresis.
The same RNA extraction method was used in labora-
tory B. The RT-PCR was carried out in a single-tube sys-
tem (Superscript One-Step RT-PCR with Platinum Taq,
Invitrogen, Carlsbad, CA), in a 25-µL reaction mix con-
taining 0.6 µmol/L of each COR-1 and COR-2 primer, 0.2
mmol/L of each deoxynucleoside triphosphate and 1.2
mmol/L magnesium sulphate. The reverse transcription
was conducted at 54°C for 30 min. After the mixture was
held at 94°C for 3 min, it underwent 45 cycles of amplifi-
cation at 94°C for 45 sec, 60oC for 45 sec, 72°C for 45 sec,
and final extension at 72°C for 7 min. The PCR amplicon
was also detected by agarose gel electrophoresis as in lab-
oratory A.
All reagent preparation, sample extraction, amplifica-
tion, and amplicon detection procedures were conducted in
separate areas and under strengthened precautions to avoid
cross-contamination. The lower detection limit of the RT-
PCR assays was determined by testing preparations with
known copies of SARS-CoV as determined by real-time
RT-PCR. Both laboratories showed a lower detection limit
of 50 viral copies per reaction. In all test runs, positive
controls containing approximately 100 copies of viral
RNA in viral transport medium were included, and double
distilled water was used as a negative control. Positive
samples were confirmed by repeating the RNA extraction
and RT-PCR from the original samples.
Virus Isolation
Virus isolation for SARS-CoV was performed in labo-
ratory B. Specimens were injected into African green mon-
key (Vero E6) cell monolayers. For stool or rectal swab
samples, the suspension was passed through a 0.45-µm fil-
ter before injection. The cell culture tubes were examined
daily for diffuse, refractile, rounding cytopathic effects
characteristic of SARS-CoV. When cytopathic effects were
observed, the cells were stained by the indirect immuno-
fluorescence technique with a convalescent-phase serum
sample collected from a SARS patient. The identity of the
isolate was further confirmed by RT-PCR.
Statistical Analysis
Statistical tests were performed by using the Statistical
Package for the Social Sciences software (SPSS 10.1.0,
Inc., Chicago, IL). The chi-square test was used to analyze
categorical variables. All statistical tests were two-tailed
and p values <0.05 were regarded as significant.
Results
Specimen Profile
Altogether, 624 respiratory specimens, 671 stool or rec-
tal swab specimens, and 314 urine specimens were collect-
ed from the 415 study patients for RT-PCR; 738
respiratory, 810 stool or rectal swab, and 531 urine speci-
mens were submitted for virus isolation; and 558 respira-
tory, 318 stool or rectal swab, and 296 urine specimens
were tested by both RT-PCR and virus isolation. The mean
number of specimens collected from each patient was 5.3
(range 1–32, SD 5.1). The mean time of collection of the
first specimen was 13.5 days (range 1–88, SD 16.5) after
the onset of symptoms (Figure 1). Patients whose first
specimens were collected at a later stage of illness had
become ill early in the outbreak when no diagnostic test
was available.
Shedding Profile
To analyze the profile of viral shedding, specimens
were grouped into categories: respiratory, stool or rectal
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swab, and urine. Respiratory specimens included tracheal
aspirate, nasopharyngeal aspirate, throat swab, throat
washing, nasal swab, and pooled throat and nasal swabs.
The viral shedding profile is shown in Figure 2; the num-
ber of specimens tested is shown in Table 1. Stool/rectal
swab specimens provided the highest positive rate by RT-
PCR, followed by respiratory and urine specimens. The
RT-PCR positive rate for respiratory specimens increased
slightly from week 1 to week 2 after the onset of illness
and then dropped to lower levels at week 3 and week 4.
The positive rate for stool/rectal swab peaked at week 2
and week 3 and then dropped sharply. The positive rate for
urine specimens increased gradually and peaked at week 4.
Viral shedding beyond week 6 was rare, with only three
stool samples (collected on day 54, day 67, and day 75,
respectively) and one respiratory sample collected on day
50 positive by RT-PCR. As for virus isolation, the latest
positive specimen was collected on day 31 for a respirato-
ry specimen, day 23 for a urine specimen, and day 6 for a
stool sample.
The RT-PCR results of specimens collected within the
first 3 weeks after the onset of illness were analyzed to fur-
ther clarify the viral shedding pattern. The positive rate for
respiratory specimens began to increase on day 5 and
remained high during the second week. The positive rate
for stool/rectal swab specimens peaked at days 9 and 10
and remained high during the second and third week,
whereas the detection rate for urine specimens started to
increase at the end of the second week (Figure 3).
Diagnostic Yield
The RT-PCR and virus isolation results of different
specimen types collected within the first 4 weeks after the
onset of symptoms are shown in Table 2. When RT-PCR
was used for virus detection, tracheal aspirate and stool
provided a high diagnostic yield, with an average positive
rate of 66.7% and 56.5%, respectively, for the first 2
weeks. Pooled throat and nasal swabs, rectal swab, nasal
swab, throat swab and nasopharyngeal aspirate provided a
moderate yield with average positive rates ranging from
29.7% to 40.0% for the first 2 weeks, whereas throat wash-
ing and urine specimens provided a lower yield with an
average positive rate of 17.3% and 4.5%, respectively. The
yield from virus isolation was much lower than from RT-
PCR, and no specimen was positive by culture but nega-
tive by RT-PCR.
RT-PCR Versus Isolation
To compare the sensitivity of RT-PCR and virus isola-
tion for detecting SARS-CoV, a subgroup analysis was
performed on 1,172 specimens that had been submitted for
both RT-PCR and virus isolation. The isolation/RT-PCR
index, defined as the number of isolation-positive speci-
mens per RT-PCR-positive specimens, was highest for res-
piratory samples, particularly for pooled throat and nasal
swabs, tracheal aspirate, and nasopharyngeal aspirate. The
isolation/RT-PCR index for stool or rectal swab samples
was approximately 5- to 10-fold lower when compared
with that for respiratory specimens (Table 3).
Positive Rate by Patient
Altogether, 132 (31.8%) of the 415 study patients had
SARS-CoV detected by RT-PCR or virus isolation. To ana-
lyze factors associated with positive virologic testing
results, a subgroup analysis was performed on 342 patients
whose first specimens were collected within 4 weeks of ill-
ness onset. Within this subgroup, 128 (37.4%) patients had
one or more positive results by RT-PCR or virus isolation.
The mean number of positive specimens among these
patients was 1.8 (range 1–10, SD 1.7). The characteristics
of patients with and without positive specimens are shown
in Table 4. A higher positive detection rate for SARS-
CoV was observed for patients with more severe disease
(p < 0.001 by chi-square test).
Laboratory Diagnosis of SARS
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Figure 1. Time of first specimen collection.
Figure 2. Positive rates of specimen groups according to time of
collection from onset of symptoms. The number of specimens test-
ed is shown in Table 1.
Discussion
Identifying the causal agent of the novel emerging
infection, SARS, shortly after recognizing its spread in
humans, was a remarkable medical accomplishment. This
achievement led to the hope for an accurate laboratory
diagnosis to guide patient management and to control the
spread of infection. During the course of the outbreak, a
few centralized laboratories were set up in Hong Kong. All
possible resources were deployed to provide a rapid diag-
nostic service for SARS patients, and a turnaround time of
24 to 48 hours was achieved for RT-PCR. From our expe-
rience, more than half of the patients did not have any pos-
itive virologic findings. For these patients, the diagnosis
could not be confirmed until a convalescent-phase serum
specimen was available at a later stage. Thoroughly under-
standing the viral shedding pattern, the diagnostic yield of
various specimen types, and various detection methods is
crucial to improve the diagnostic performance.
For most acute respiratory viral infections, the maximal
viral shedding occurs in the first few days after illness
onset and seldom lasts for more than 10 days (12–14).
However, our data indicated that respiratory shedding of
SARS-CoV increased over the first week and remained
high during the second week. In addition, respiratory shed-
ding >2 weeks after the onset of symptoms was common.
This pattern of respiratory shedding is consistent with a
previous report of a community outbreak in Hong Kong
(15). We found that the peak of viral shedding in stool
occurred a few days after that of respiratory shedding. The
ability to detect virus in stool specimens peaked at the
beginning of the second week and remained high over
week 3 and week 4. Occasionally, the shedding of virus in
stool could last for more than 6 weeks after the onset of
symptoms. The viral shedding peak in urine occurred even
later, at weeks 3–4.
In summary, viral shedding of SARS-CoV peaks at a
time later than expected and occurs when patients are
being hospitalized. This, together with the prolonged viral
shedding, could partly explain the propensity for this
infection to be transmitted in healthcare settings. We
observed that all those who shed virus for a prolonged
period (arbitrarily defined as the shedding viruses >6
weeks after onset of symptoms) had their positive samples
collected while still critically ill and had received intensive
care. The infectiousness of these patients is difficult to dis-
cuss because the virus was detected by RT-PCR but not by
virus isolation. Nevertheless, further investigations on
whether the adverse outcome could be related to inade-
quate viral clearance are worth pursuing.
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Table 1. Specimens tested after onset of illness 
Specimen type 
Stool/rectal swab Respiratory Urine 
Collection time (wk) RT-PCRa Virus isolation RT-PCR Virus isolation RT-PCR Virus isolation 
1 32 38 243 280 75 110 
2 35 40 134 153 82 86 
3 44 84 57 62 33 41 
4 43 92 37 36 21 35 
5 96 113 41 57 29 64 
6 110 123 30 50 26 72 
7 80 84 18 30 9 38 
8 54 55 14 22 10 33 
9 49 52 16 27 6 26 
10 34 35 16 12 9 10 
11 44 44 10 5 9 11 
12 21 21 4 2 2 3 
13 16 16 2 1 2 1 
14 7 7 2 1 1 1 
15 5 5 0 0 0 0 
16 1 1 0 0 0 0 
aRT-PCR, reverse transcription–polymerase chain reaction. 
Figure 3. Positive rates of specimens collected within the first 3
weeks.
Available data that compare the diagnostic yield of var-
ious specimen types are still limited. Wu et al. found that
virus was detected in 73% (49/67) of liquid nasopharyn-
geal gargling samples by a fluorescent PCR (16).
However, our data showed that throat washing samples
were the most inferior respiratory specimens. In addition
to the difference in the sensitivity of detection assays used,
the procedures of gargle sample collection could have
affected the diagnostic yield. Yam et al. reported that
nasopharyngeal aspirate specimens collected between days
1 and 5 after admission provided a similar diagnostic yield
when compared to stool samples collected between days 5
and 10 (17). However, data comparing respiratory and
stool specimens collected at the same period were not
available in their study. In an investigation on a communi-
ty outbreak in Hong Kong, Peiris et al. reported that respi-
ratory viral shedding peaked during the second week (15).
A high positive rate was also obtained from stool samples
collected during the second week, but the yield for first
week stool samples was not available for comparison.
Nasopharyngeal aspirate is generally regarded as the
specimen of choice for detecting respiratory viruses.
However, for SARS, the great risk of generating infectious
aerosols during the aspiration procedure needs to be con-
sidered. We found that pooled throat and nasal swab spec-
imens provided a higher diagnostic yield compared with
nasopharyngeal aspirates. Our data indicate that a combi-
nation of stool sample and pooled throat and nasal swab
specimens should be the specimens of choice for a safe and
high-yield SARS-CoV detection. In situations where spec-
imen load is high, pooling of stool sample with throat and
nasal swabs for RT-PCR can be considered to minimize the
reagent and personnel costs.
SARS-CoV was first isolated from a monkey kidney
cell line and is known to produce characteristic cytopathic
effects after a few days of incubation in Vero or Vero E6
cell monolayers. At present, the ideal in vitro growth con-
ditions have not yet been elucidated. Our data on isola-
tion/RT-PCR index showed that about 10%–50% of the
RT-PCR–positive respiratory and urine specimens had
virus grown from Vero E6 cell culture. However, stool and
rectal swab specimens had a much lower isolation/RT-PCR
index. The presence of toxic substances in stool or rectal
swab samples may have interfered with virus isolation.
However, toxicity was only occasionally observed on Vero
E6 monolayers after adding stool or rectal swab samples.
Laboratory Diagnosis of SARS
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Table 2. Diagnostic yield of specimen types to detect SARS-CoV according to time of collection  
 No. positive specimens/no. tested for SARS-CoV (%) 
 RT-PCR Virus isolation 
Specimen type 1 week 2 weeks 3–4 weeks 1 week 2 weeks 3–4 weeks 
Respiratory       
Tracheal aspirate 1/2 (50.0) 1/1 (100) 4/4 (100) 2/3 (66.7) 1/1 (100) 0/3 
Pooled throat and nasal swabs 6/17 (35.3) 2/3 (66.7) 2/5 (40.0) 4/18 (22.2) 0/3 0/1 
Nasal swab 9/27 (33.3) 5/14 (35.7) 1/17 (5.9) 3/29 (10.3) 2/18 (11.1) 0/19 
Nasopharyngeal aspirate 39/138 (28.3) 15/44 (34.1) 6/10 (60.0) 23/171 (13.5) 6/54 (11.1) 0/9 
Throat swab 5/19 (26.3) 5/14 (35.7) 3/10 (30.0) 2/23 (8.7) 0/15 1/15 (6.7) 
Throat washing 4/40 (10.0) 13/58 (22.4) 1/48 (2.1) 0/36 1/62 (1.6) 0/51 
Nonrespiratory       
Rectal swab 5/11 (45.5) 2/10 (20.0) 3/7 (42.9) 0/14 0/12 0/35 
Stool 9/21 (42.9) 17/25 (68.0) 34/80 (42.5) 2/24 (8.3) 0/28 0/141 
Urine 2/75 (2.7) 5/82 (6.1) 6/54 (11.1) 0/110 0/86 2/76 (2.6) 
aSARS-CoV, severe acute respiratory syndrome–associated coronavirus; RT-PCR, reverse transcription–polymerase chain reaction. 
Table 3. Comparison on positive rates of RT-PCR and virus isolationa 
No. (%) of specimens tested positiveb 
Specimen type (no.) RT-PCR Virus isolation Isolation/RT-PCR indexc 
Pooled throat and nasal swab (30) 8 (26.7) 4 (13.3) 0.50 
Tracheal aspirate (13) 6 (46.2) 2 (15.4) 0.33 
Nasopharyngeal aspirate (183) 52 (28.4) 14 (7.7) 0.27 
Throat swab (58) 11 (19.0) 2 (3.4) 0.18 
Nasal swab (56) 14 (25.0) 2 (3.6) 0.14 
Urine (296) 14 (4.7) 2 (0.7) 0.14 
Throat washing (218) 17 (7.8) 1 (0.5) 0.06 
Stool (262) 70 (26.7) 2 (0.8) 0.03 
Rectal swab (56) 12 (21.4) 0 (0) 0 
aRT-PCR, reverse transcription–polymerase chain reaction. 
bOnly specimens tested by both RT-PCR and virus isolation are included. 
cNo. of isolation-positive specimens per RT-PCR-positive specimen. 
SARS-CoV can survive for at least 2–4 days at room tem-
perature when mixed with diarrheal or normal stool speci-
mens (18). Thus, the poor isolation rate could not be a
result of viral inactivation by fecal contents during speci-
men storage and transport. The big difference in isolation
rate from stool compared to respiratory and urine samples
deserve further investigation, and the possibility of viral
growth interference due the presence of IgA antibodies
needs to be considered.
We found that positive virologic results were associat-
ed with more adverse outcomes in patients. This observa-
tion could be confounded by the fact that only high-yield
specimens, e.g., tracheal aspirate, could be obtained from
intubated patients. We verified this point by examining the
results of testing other samples from patients with viruses
detected from tracheal aspirate samples. We found that all
except one of these patients also had viruses detected from
other specimen types. Thus, our observations are in line
with the fact that more severely affected patients shed a
higher load of virus, which facilitated the detection of the
virus. 
Several options could be considered to improve the
ability to accurately diagnose SARS-CoV infection. First,
detection of viremia should be included in the diagnostic
algorithm because we have found SARS-CoV RNA from
blood samples taken within the first few days of onset of
symptoms. If this approach is successful, it will close the
gap caused by lower virus shedding from the gastrointesti-
nal or respiratory tract that occurs in the first few days after
the onset of symptoms. Second, a SARS-CoV-specific
monoclonal antibody would be valuable in developing an
immunofluorescence assay to detect virus-infected cells
from respiratory samples. Such an approach has been
shown to provide high sensitivity for influenza and respi-
ratory syncytial viruses. Third, an assay should be devel-
oped to detect viral antigens from stool samples as is
available for rotavirus detection. Further work to improve
the sensitivity and specificity of diagnostic assays for
SARS-CoV is needed. The unusual shedding pattern of
SARS-CoV should be considered when formulating infec-
tion control strategies.
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